The General Electric (GE) of medical devices.

A more diversified version of Abbott Laboratories, focused solely on advanced medical devices.

Like Johnson & Johnson's medical device division, but as a standalone company making an even wider array of critical surgical and implantable technologies.

• Cardiac Rhythm & Heart Failure Devices: Implantable pacemakers, defibrillators, cardiac resynchronization therapy devices, AF ablation products, and insertable cardiac monitors for managing heart conditions.
• Vascular & Structural Heart Products: Aortic valves, stents, surgical valve replacement/repair products, endovascular stent grafts, and angioplasty balloons for treating vascular and structural heart diseases.
• Mechanical Circulatory Support: Devices that assist the heart in pumping blood for patients with heart failure.
• Surgical Devices & Robotics: Surgical stapling devices, vessel sealing instruments, wound closure products, electrosurgery products, and robotic-assisted surgery systems.
• Hernia & Women's Health Products: Mechanical devices and mesh implants for hernia repair, and products for gynecology and lung conditions.
• Spinal & Neurological Surgical Systems: Image-guided surgery, intra-operative imaging, and robotic guidance systems for spine and neurosurgery.
• Neurovascular Therapies: Products and therapies specifically designed to treat conditions affecting the blood vessels in and around the brain.
• Insulin Pumps & Consumables: Devices that deliver insulin continuously for diabetes management.
• Continuous Glucose Monitoring Systems (CGM): Systems that provide real-time glucose level readings for people with diabetes.

Medtronic (MDT) primarily sells its device-based medical therapies to other companies and institutions. Its major customers can be categorized as follows:

• Hospitals and Healthcare Systems: These are the primary institutional buyers for the vast majority of Medtronic's products across its Cardiovascular, Neuroscience, and Medical Surgical portfolios. This includes large public and private hospital chains, university hospitals, and integrated delivery networks that acquire devices for use in surgeries, diagnostics, and long-term patient care. While Medtronic sells to these types of companies globally, the provided background information does not list the specific names of these customer companies.
• Surgical Centers and Clinics: These facilities also serve as significant customers, purchasing Medtronic's specialized devices and therapies, particularly for outpatient procedures and specific clinical needs. Physicians and clinicians, mentioned in the company description, generally procure Medtronic products through these institutional channels.

In addition to selling to the aforementioned companies, Medtronic's Diabetes Operating Unit directly serves **individual patients** with products such as insulin pumps and continuous glucose monitoring systems.

Geoff Martha - Chairman and Chief Executive Officer

Geoff Martha is the Chairman and Chief Executive Officer of Medtronic, having been appointed CEO in April 2020 and Chairman later that year. He joined Medtronic in 2011 and has held various leadership positions, including SVP, Strategy and Business Development; Chief Integration Officer; and Executive Vice President, Restorative Therapies Group. Notably, he led the acquisition and integration of Covidien, which was the largest acquisition in the medical technology industry. Before joining Medtronic, Martha spent 19 years at GE Healthcare and GE Capital, where he held various business development, strategic marketing, and sales management roles. He holds a bachelor's degree in Finance from Pennsylvania State University.

Thierry Piéton - Executive Vice President and Chief Financial Officer

Thierry Piéton was appointed Executive Vice President and Chief Financial Officer of Medtronic, with his role becoming effective on March 3, 2025. Prior to joining Medtronic, Piéton served as Chief Financial Officer of Renault Group starting in March 2022, where he was recognized for achieving record-high operating margins and improving free cash flow. His extensive background also includes experience at Nissan Motor Co. Ltd, General Electric (GE), GE Healthcare, and PricewaterhouseCoopers, showcasing a career built across multiple industries and geographies.

Brett A. Wall - Executive Vice President and President, Neuroscience Portfolio

Brett A. Wall serves as the Executive Vice President and President of Medtronic's Neuroscience Portfolio.

Harry S. Kiil - Executive Vice President and President, Cardiovascular Portfolio

Harry S. Kiil, also known as Skip Kiil, is the Executive Vice President and President of the Cardiovascular Portfolio at Medtronic.

Mike Marinaro - Executive Vice President and President, Medical Surgical Portfolio and Americas

Mike Marinaro holds the position of Executive Vice President and President of the Medical Surgical Portfolio and Americas at Medtronic.

Key Risks to Medtronic (MDT)

1. Intense Competition and Pricing Pressures: Medtronic operates in a highly competitive medical technology industry characterized by rapid technological advancements and the continuous emergence of new competitors. This environment necessitates constant innovation to maintain market leadership and defend market share. Additionally, the company faces significant pricing pressures from healthcare cost containment initiatives and increased price sensitivity among customers, which can negatively impact profitability and require adjustments in pricing strategies. For example, in the diabetes care segment, competitors are expected to capture a majority of new durable pump users, putting pressure on Medtronic's market position.
2. Regulatory and Legal Challenges: As a global medical device company, Medtronic is subject to stringent regulatory oversight in numerous jurisdictions, leading to costly compliance requirements and potential legal disputes. Delays in regulatory approvals can hinder the company's ability to bring new innovations to market, affecting its competitive edge and revenue growth. Furthermore, changes in healthcare policies, reimbursement rates, and intellectual property litigation pose ongoing threats that can impact operations, market access, and financial performance. The company must navigate complex global regulatory landscapes, which can be resource-intensive.
3. Supply Chain Dependencies and Geopolitical/Tariff Risks: Medtronic faces operational risks stemming from its complex global supply chain, including vulnerabilities due to reliance on sole suppliers for certain components and raw materials. Disruptions or interruptions in the supply chain can affect manufacturing and product availability, potentially damaging the company's reputation and customer relationships. Moreover, extensive international operations expose Medtronic to geopolitical risks, currency fluctuations, and varying economic conditions. The potential return to higher tariff rates, particularly on goods from China, is identified as a significant financial headwind that could impact earnings and margins.

The rise of highly effective glucagon-like peptide-1 (GLP-1) receptor agonist drugs (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) represents a clear emerging threat, particularly to Medtronic's Diabetes Operating Unit. These drugs are demonstrating significant efficacy in weight loss and improving glycemic control for patients with type 2 diabetes and obesity. For a segment of the diabetic population, particularly those in earlier stages of type 2 diabetes or those currently using less intensive insulin regimens, these pharmaceutical advancements could reduce or even eliminate the need for insulin pumps and potentially continuous glucose monitoring systems by effectively managing their condition through medication. This could shrink the addressable market for Medtronic's device-based diabetes management therapies.

Medtronic (symbol: MDT) operates across several significant medical device markets globally. The addressable markets for its main products and services are sized as follows:

• Cardiac Rhythm Management Devices (Implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices): The global market for cardiac rhythm management devices was estimated at USD 23.87 billion in 2025 and is projected to reach approximately USD 43.19 billion by 2035. North America is a dominant region, holding over 46% of the market share in 2025.
• Structural Heart Devices (Aortic valves, surgical valve replacement and repair products): The global structural heart devices market size was estimated at USD 16.13 billion in 2024 and is projected to reach USD 50.99 billion by 2033. North America dominated the global market in 2024, accounting for the largest revenue share of 52.5%.
• Interventional Cardiology and Peripheral Vascular Devices (Percutaneous coronary intervention stents, endovascular stent grafts, percutaneous angioplasty balloons, products to treat superficial venous diseases): The global interventional cardiology and peripheral vascular devices market was valued at USD 27.7 billion in 2025 and is projected to grow to USD 60.8 billion by 2035. North America is identified as the largest market in this segment.
• Surgical Robotics: The global surgical robotics market size was valued at USD 10.76 billion in 2024 and is forecasted to reach around USD 45.93 billion by 2034. The U.S. surgical robotics market size alone was USD 3.84 billion in 2024.
• Hernia Repair Devices (Hernia mechanical devices, mesh implants): The global hernia repair devices market size was USD 5.64 billion in 2025 and is anticipated to reach approximately USD 9.22 billion by 2035.
• Neurovascular Devices (Therapies for vasculature in and around the brain): The global neurovascular devices market size is calculated at USD 7.80 billion in 2025 and is projected to reach around USD 13.69 billion by 2035. North America led the global neurovascular devices market share by 28% in 2024.
• Pain Management Devices: The global pain management devices market was valued at USD 7.70 billion in 2024 and is expected to reach USD 14.31 billion by 2032.
• Urology Devices: The global urology devices market size was USD 39.03 billion in 2025 and is projected to grow to USD 75.48 billion by 2034. North America dominated this market with a share of 37.11% in 2025.
• Insulin Pumps: The global insulin pump market size was valued at USD 7.05 billion in 2025 and is projected to grow to USD 22.45 billion by 2034. North America dominated the market with a 57.34% market share in 2025.
• Continuous Glucose Monitoring (CGM) Systems: The global Continuous Glucose Monitoring (CGM) Systems Market is projected to expand from USD 12,835.6 million in 2025 to USD 55,048.4 million by 2035. In 2024, the market generated USD 11,096.4 million in revenue.

Medtronic (MDT) is expected to drive future revenue growth over the next 2-3 years through several key strategies and product advancements:

1. Innovation and New Product Launches Across Key Portfolios: Medtronic is focused on launching new, innovative products in high-growth areas. Significant drivers include the pulsed field ablation (PFA) platform for AFib, which has shown rapid growth within the Cardiac Ablation Solutions business, with Medtronic aiming to double revenue in this segment to $2 billion by the first half of fiscal year 2027. Additionally, the Hugo robotic surgical system, having received FDA approval, is anticipated to unlock substantial market opportunities in the U.S. The Neuroscience Portfolio also contributes with new offerings such as the Stealth AXiS surgical system and an Adaptive deep brain stimulation (DBS) system.
2. Growth in the Diabetes Operating Unit: The Diabetes Operating Unit is a significant revenue growth driver, primarily through the continued adoption of the MiniMed™ 780G automated insulin delivery system and the global rollout of the next-generation Simplera Sync™ sensor. The company has also secured expanded indications for its diabetes technologies, including for insulin-requiring Type 2 diabetes and younger pediatric populations.
3. Expansion into Emerging Markets: Medtronic is strategically expanding its presence in international markets, particularly focusing on emerging markets like China. This expansion aims to achieve sustainable double-digit growth by introducing cost-effective surgical products and increasing the attachment rates of Continuous Glucose Monitoring (CGM) systems.
4. Strong Performance in Cardiac Ablation Solutions (CAS): The Cardiac Ablation Solutions business, bolstered by its pulsed field ablation (PFA) portfolio, is experiencing substantial growth. This segment has shown significant year-over-year growth and is gaining market share, with the company expecting to double its revenue.

Share Repurchases

• Medtronic's annual share buybacks were $3.235 billion in 2025, $2.138 billion in 2024, and $645 million in 2023.
• Medtronic repurchased $105 million in shares for the quarter ending December 31, 2025.
• The company aims to return a minimum of 50% of its free cash flow to shareholders.

Share Issuance

• Medtronic's shares outstanding saw a 3.03% decline from 2024 to 2025, a 0.2% decline from 2023 to 2024, and a 1.38% decline from 2022 to 2023, indicating net repurchases.
• As of March 2026, the number of shares outstanding for Medtronic was 1.282 billion.

Outbound Investments

• Medtronic completed the acquisition of Scientia Vascular in March 2026 for $550 million.
• The company made a Post IPO investment in Orchestra BioMed on July 31, 2025, and a Series D investment in FIRE1 on January 7, 2025.
• Medtronic maintains "significant firepower" to pursue acquisitions, particularly in cardiology and neuroscience, targeting deals in the low- to mid-single-digit billions of dollars to supplement internal R&D efforts.

Capital Expenditures

• Medtronic's capital expenditures were $1.859 billion in 2025, $1.587 billion in 2024, and $1.459 billion in 2023.
• Capital expenditures have increased consistently over the last five fiscal years, from $1.355 billion in 2021 to $1.859 billion in 2025.
• Medtronic invested an estimated $65 million in the expansion of its manufacturing operations in Costa Rica, a process that began in 2020 and continued until 2024, with a focus on producing surgical components for spinal surgeries.